Stay updated on Pembrolizumab in Untreated Extensive SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page.

Latest updates to the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page
- Check2 days agoChange DetectedA funding note for 2014 NIH Grant/Contract was added and the page revision was updated to v3.6.6, with the previous revision v3.6.5 removed.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedThe page now displays a generic error screen indicating the requested content is temporarily unavailable, replacing the usual study record content. This reflects a site error rather than a substantive update to the study data.SummaryDifference17%

- Check38 days agoChange DetectedRevision tag updated from v3.6.3 to v3.6.4 to reflect a site update; study content and presentation remain unchanged.SummaryDifference0.0%

- Check59 days agoChange DetectedThe page's revision/version indicator was updated from v3.6.2 to v3.6.3, signaling a new release of the page. This change represents an update to the page version rather than a modification of study content.SummaryDifference0.0%

- Check66 days agoChange DetectedRevision indicator on the page updated from v3.6.0 to v3.6.2, indicating a newer version of the page content.SummaryDifference0.0%

- Check80 days agoChange DetectedNew user guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) have been added, and the Intervention / Treatment heading was updated to Intervention/Treatment with a page revision tag showing v3.6.0. The recruitment status was updated to No longer looking for participants, indicating enrollment is closed.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab in Untreated Extensive SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page.